• Implantica secured FDA approval for its RefluxStop device, clearing entry into the U.S. market.
• The company plans a targeted rollout at selected U.S. reflux surgery centers, with adoption expected to build gradually.
• RefluxStop has several years of European commercial use, with about 1,800 patients treated and five-year clinical outcomes published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via Cision (Ref. ID: 20260820:BIT:0360:0) on August 20, 2026, and is solely responsible for the information contained therein.